UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Renal Transporters in Drug Development

Annual review of pharmacology and toxicology, 2013-01, Vol.53 (1), p.503-529

2013

Volltextzugriff (PDF)

OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin

Proceedings of the National Academy of Sciences - PNAS, 2014-07, Vol.111 (27), p.9983-9988

2014

Volltextzugriff (PDF)

Discovery of Potent, Selective Multidrug and Toxin Extrusion Transporter 1 (MATE1, SLC47A1) Inhibitors Through Prescription Drug Profiling and Computational Modeling

Journal of medicinal chemistry, 2013-02, Vol.56 (3), p.781-795

2013

Volltextzugriff (PDF)

A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer

Breast cancer research : BCR, 2018-09, Vol.20 (1), p.109-12, Article 109

2018

Volltextzugriff (PDF)

First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma

Clinical cancer research, 2020-04, Vol.26 (8), p.1820-1828

2020

Volltextzugriff (PDF)

Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting

Cancer chemotherapy and pharmacology, 2019-12, Vol.84 (6), p.1257-1267

2019

Volltextzugriff (PDF)

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

Journal for immunotherapy of cancer, 2018-06, Vol.6 (1), p.61-12, Article 61

2018

Volltextzugriff (PDF)

Genome-wide discovery of drug-dependent human liver regulatory elements

PLoS genetics, 2014-10, Vol.10 (10), p.e1004648

2014

Volltextzugriff (PDF)

Computational analysis of kinase inhibitor selectivity using structural knowledge

Bioinformatics, 2019-01, Vol.35 (2), p.235-242

2019

Volltextzugriff (PDF)

The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers

Clinical pharmacokinetics, 2016-04, Vol.55 (4), p.495-506

2016

Volltextzugriff (PDF)

Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors

Nature cancer, 2023-04, Vol.4 (4), p.485-501

2023

Volltextzugriff (PDF)

Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction

Drug metabolism and disposition, 2008-11, Vol.36 (11), p.2355-2370

2008

Volltextzugriff (PDF)

Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor

British journal of clinical pharmacology, 2019-08, Vol.85 (8), p.1751-1760

2019

Volltextzugriff (PDF)

The Patient‐Centered Future of Clinical Pharmacology

Clinical pharmacology and therapeutics, 2020-01, Vol.107 (1), p.72-75

2020

Volltextzugriff (PDF)

Combining “Bottom‐up” and “Top‐down” Approaches to Assess the Impact of Food and Gastric pH on Pictilisib (GDC‐0941) Pharmacokinetics

CPT: pharmacometrics and systems pharmacology, 2017-11, Vol.6 (11), p.747-755

2017

Volltextzugriff (PDF)

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

Clinical cancer research, 2019-06, Vol.25 (11), p.3220-3228

2019

Volltextzugriff (PDF)

The Effect of Novel Promoter Variants in MATE1 and MATE2 on the Pharmacokinetics and Pharmacodynamics of Metformin

Clinical pharmacology and therapeutics, 2013-02, Vol.93 (2), p.186-194

2013

Volltextzugriff (PDF)

Expanding the Role of the Dynein Regulatory Complex to Non‐Axonemal Functions: Association of GAS11 with the Golgi Apparatus

Traffic (Copenhagen, Denmark), 2006-05, Vol.7 (5), p.538-548

2006

Volltextzugriff (PDF)

Abstract P193: AMX-818, a novel prodrug HER2-XPAT T-cell engager (TCE) with potent T cell activation, proteolytic cleavage and efficacy in xenograft tumors, and wide safety margins in NHP (Non Human Primate)

Molecular cancer therapeutics, 2021-12, Vol.20 (12_Supplement), p.P193-P193

2021

Volltextzugriff (PDF)

A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non–small cell lung cancer

European journal of cancer (1990), 2017-11, Vol.86, p.186-196

2017

Volltextzugriff (PDF)

A validated surrogate analyte LC-MS/MS assay for quantitation of endogenous kynurenine and tryptophan in human plasma

Bioanalysis, 2018-08, Vol.10 (16), p.1307-1317

2018

Volltextzugriff (PDF)

Consequences of POR mutations and polymorphisms

Molecular and cellular endocrinology, 2011-04, Vol.336 (1-2), p.174-179

2011

Volltextzugriff (PDF)

Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro

Pharmacogenetics and genomics, 2010-11, Vol.20 (11), p.677-686

2010

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(32)
Dissertationen
(1)

Sprache

Englisch
(33)

Erscheinungsjahr

n.n

Thema

Science & Technology
(25)
Life Sciences & Biomedicine
(24)
Humans
(20)
Female
(11)
Pharmacology & Pharmacy
(11)
Male
(9)
Oncology
(9)
Adult
(8)
Middle Aged
(7)
Pharmacokinetics
(7)
Aged
(5)
Animals
(5)
Biological And Medical Sciences
(4)
Cancer
(4)
Drug Metabolism
(4)
Enzymes
(4)
Genetics & Heredity
(4)
Immunotherapy
(4)
Indoleamine-Pyrrole 2,3,-Dioxygenase - Antagonists & Inhibitors
(4)
Medical Sciences
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Renal Transporters in Drug Development

OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin

Discovery of Potent, Selective Multidrug and Toxin Extrusion Transporter 1 (MATE1, SLC47A1) Inhibitors Through Prescription Drug Profiling and Computational Modeling

A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer

First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma

Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

Genome-wide discovery of drug-dependent human liver regulatory elements

Computational analysis of kinase inhibitor selectivity using structural knowledge

The Effect of Nizatidine, a MATE2K Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Volunteers

Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors

Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction

Investigation of the absolute bioavailability and human mass balance of navoximod, a novel IDO1 inhibitor

The Patient‐Centered Future of Clinical Pharmacology

Combining “Bottom‐up” and “Top‐down” Approaches to Assess the Impact of Food and Gastric pH on Pictilisib (GDC‐0941) Pharmacokinetics

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors

The Effect of Novel Promoter Variants in MATE1 and MATE2 on the Pharmacokinetics and Pharmacodynamics of Metformin

Expanding the Role of the Dynein Regulatory Complex to Non‐Axonemal Functions: Association of GAS11 with the Golgi Apparatus

Abstract P193: AMX-818, a novel prodrug HER2-XPAT T-cell engager (TCE) with potent T cell activation, proteolytic cleavage and efficacy in xenograft tumors, and wide safety margins in NHP (Non Human Primate)

A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non–small cell lung cancer

A validated surrogate analyte LC-MS/MS assay for quantitation of endogenous kynurenine and tryptophan in human plasma

Consequences of POR mutations and polymorphisms

Abstract CT302: Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors

Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Patients with Advanced Solid Tumors

Suchergebnisse filtern